share_log

Avricore Health CEO Hosts Investor Call December 15th

Avricore Health CEO Hosts Investor Call December 15th

Avricore Health首席執行官12月15日主持投資者電話會議
GlobeNewswire ·  2021/12/09 14:00

VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or "AVCR") will host a year end update and look ahead discussion by the Company's CEO and key team members.

温哥華,不列顛哥倫比亞省,2021年12月9日(環球通訊社)AVRICORE Health Inc.(TSXV:AVCR)(“公司“或”AVCR“)將主持一次年終更新,並展望公司首席執行官和主要團隊成員的未來討論。

"We've had our best year yet, despite many external factors that created headwinds, and we're extremely excited to head into 2022," said Avricore Health CEO, Hector Bremner. "Given that we are well capitalized and have executed several key agreements already, we're well positioned for growth."

Avricore Health首席執行官赫克託·佈雷姆納(Hector Bremner)説:“儘管有許多外部因素造成了逆風,但我們度過了最好的一年,我們對進入2022年感到非常興奮。”“考慮到我們的資本充足,而且已經簽署了幾項關鍵協議,我們已經為增長做好了準備。”

Call Details:

通話詳細信息:

December 15th, 2021 @ 10:00am PT / 1:00pm ET via Zoom
(Link and access codes shared upon registration)

12月15日,2021@太平洋時間上午10:00/東部時間下午1:00通過Zoom(註冊時共享鏈接和訪問代碼)

Agenda:

議程:

The 60-minute call agenda will be as follows:

60分鐘的電話會議議程如下:

  • 10min: Opening Remarks / Team Introductions
  • 20Min: Overview Presentation and Update
  • 30Min: Q&A
  • 10分鐘:開場白/團隊介紹
  • 20分鐘:概述演示文稿和更新
  • 30分鐘:問答

To register, please email your contact details (Name, Phone) to: investor@avricorehealth.com. You will receive log-in instructions and access codes prior to the meeting. Also, please feel free to review our most recent investor presentation here:

要註冊,請通過電子郵件發送您的聯繫方式(姓名、電話)至:Investors@avricoreHealth.com。您將在會議前收到登錄説明和訪問代碼。此外,請隨時在此處查看我們最新的投資者演示文稿:

About HealthTab™

關於HealthTab™

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.
The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

HealthTab™是一款交鑰匙醫療設備測試解決方案,它將同類最佳的醫療設備技術與基於雲的安全平台相結合,用於解決緊迫的全球健康問題。只需手指扎出幾滴血,該系統就能在現場生成實驗室準確的結果,並實時報告數據。測試菜單包括多達23個用於篩選和管理慢性疾病的關鍵生物標記物,如糖尿病和心臟病(例如,HbA1c、血脂分佈、EGFR)。HealthTab™最近還增加了細菌和病毒檢測功能,如鏈球菌和新冠肺炎。HealthTab™網絡模型與當今藥劑業的任何模式都不同。它使知識淵博和值得信賴的藥劑師在初級保健服務中發揮更大的作用,同時使患者能夠更好地控制自己的健康。它還減少了成本和等待時間,並提供了許多潛在的收入來源,包括設備租賃和耗材、直接訪問測試、疾病預防和管理計劃、贊助健康計劃、分散臨牀試驗、真實世界數據(RWD)集,以及通過API集成第三方應用程序。

About Avricore Health Inc.

關於Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Avricore Health Inc.(多倫多證券交易所股票代碼:AVCR)是一家藥房服務創新者,專注於獲取和開發旨在推動藥房向前發展的早期技術。通過其全資子公司HealthTab™的旗艦產品,該公司的使命是通過在社區藥店創建世界上最大的快速檢測設備網絡,使每個人都更容易獲得可操作的健康信息。

Contact:

聯繫人:

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com 

Avricore Health Inc.首席執行官赫克託·佈雷姆納(Hector Bremner),電話:604-773-8943郵箱:info@avricoreHealth.comWww.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

有關前瞻性陳述的注意事項本新聞稿中涉及Avricore Health對未來的預期、計劃、意圖或戰略的信息均為前瞻性陳述,不是事實,涉及許多風險和不確定性。Avricore Health通常使用諸如“展望”、“將會”、“可能”、“可能”、“仍然”、“將要”、“計劃”、“相信”、“可能”、“預期”、“打算”、“預期”、“估計”、“未來”、“定位”、“潛在”、“項目”、“保持”、“預定”、“設置為“受制於”、“即將到來”以及類似的表達方式,以幫助識別前瞻性陳述。在本新聞稿中,前瞻性陳述包括有關以下方面的陳述:配售完成及其預期時間和公司預期配售收益的使用;HealthTab™平台向藥劑師和患者提供的獨特功能。前瞻性陳述反映了當時對Avricore Health管理層的預期、信念、假設、估計和預測。本新聞稿中的前瞻性陳述基於截至本新聞稿發佈之日Avricore Health可獲得的信息。前瞻性陳述在作出時被認為是真實的,但最終可能被證明是不正確的。這些陳述不是對Avricore Health公司未來業績的保證,會受到一些風險、不確定因素和其他因素的影響,其中一些風險、不確定因素和其他因素是Avricore Health公司無法控制的,可能導致實際結果與目前的預期大不相同,包括但不限於:未能滿足監管要求;市場變化;經濟狀況的潛在下滑;以及Avricore公司公開申報文件中描述的其他風險因素。這些前瞻性陳述僅説明截止日期。, 除非法律另有要求,否則公司沒有義務公開更新這些信息,以反映新的信息或未來事件或情況的發生。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this statement.

多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本聲明的充分性或準確性承擔責任。


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論